Powder: -20°C for 3 years
In solvent: -80°C for 2 years
FT671 is a non-covalent and selective inhibitor of USP7 (IC50: 52 nM) It also binds to the USP7 catalytic domain (Kd: 65 nM).
Description | FT671 is a non-covalent and selective inhibitor of USP7 (IC50: 52 nM) It also binds to the USP7 catalytic domain (Kd: 65 nM). |
Targets&IC50 | USP7:52 nM |
In vitro | FT671 causes the degradation of N-Myc and upregulation of p53 in the neuroblastoma cell line IMR-32. FT671 increases p53 protein levels in HCT116 or bone osteosarcoma (U2OS) cell lines, leading to the induction of p53 target genes including BBC3 (which encodes PUMA), CDKN1A (p21), RPS27L (S27L) and MDM2. FT671 also stabilizes p53 in the MM.1S multiple myeloma cell line, which correlates with increased MDM2 ubiquitination and leads to the expression of p53 target genes. |
In vivo | FT671 is well-to related even at high doses. FT671 (100 mg/kg and 200 mg/kg, oral gavage, daily) treatment in mice causes an obviously dose-dependent inhibition of tumor growth. |
Molecular Weight | 533.48 |
Formula | C24H23F4N7O3 |
CAS No. | 1959551-26-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 50 mg/mL (93.72 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FT671 1959551-26-8 DNA损伤和修复 泛素化 细胞周期 DUB FT-671 Inhibitor inhibitor inhibit